Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C6ID
|
|||
| Former ID |
DIB015851
|
|||
| Drug Name |
Citatuzumab bogatox
|
|||
| Synonyms |
VB6-845; Antibody therapeutic (ovary tumor), Viventia; Ovary cancer therapeutic (antibody), Viventia; Anti-EpCAM-bouganin conjugate (anticancer), Viventia
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Viventia Biotech Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tumor-associated calcium signal transducer 1 (EPCAM) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00481936) Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin. U.S. National Institutes of Health. | |||
| REF 2 | Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm. 2012 Nov;27(9):582-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.